Introduction
Hepatic tumors are the most common gastrointestinal tract malignancy worldwide (1) . Surgical resection is the most effective treatment for hepatic tumors; however, recurrence is frequent and usually occurs in the liver (2) . In addition, resection, a procedure commonly used as therapy for liver cancer, may accelerate the growth of local residual cancer (3, 4) . Previous studies in our laboratory demonstrated that enhancement of Kupffer cell (KC) 1 tumoricidal activity by systemic administration of the immunomodulator ␥ IFN significantly reduces the uptake and growth of hepatic tumor found in a metastatic model (4) . The current study attempts to determine if stimulation of the lymphocyte antitumor mechanisms is complementary to the macrophage tumoricidal mechanisms.
One of the most successful strategies directed at stimulating lymphocyte antitumor immunity is the use of cytokines, such as IL-2 and GM-CSF. IL-2 is a protein (synthesized and secreted primarily by T helper cells) which activates lymphocytes (5); GM-CSF is produced by a wide range of cell types including B and T cells, macrophages, and endothelial cells, and it functions to stimulate proliferation, maturation, and function of hematopoietic cells (6) . The high systemic levels of cytokines required to produce an antitumor response in humans have led researchers to examine whether local cytokine production in the presence of tumor antigens could be effective without the toxicity associated with high systemic levels (7) . Several gene therapy models utilizing IL-2-and GM-CSFsecreting tumor vaccines have demonstrated these cytokines' ability to stimulate the immune system, and to produce protective immunity in both rat and murine systems (8) (9) (10) (11) (12) .
Herpes Simplex virus amplicon (HSV) vectors are efficient vehicles for introducing foreign genes into cells. HSV vectors rapidly infect cells, transducing them in a matter of minutes with high local expression of the foreign gene for a limited duration (13) (14) (15) . In the current experiments, this transient expression allows us to distinguish immunologic responses from effects due to ongoing cytokine production. We constructed replication-defective HSV amplicon vectors containing the genes for IL-2, GM-CSF, or LacZ in order to examine whether gene799 therapy with tumor cells tailored by HSV vectors to produce cytokines could induce immunity and decrease metastatic tumor uptake and growth. We sought to determine if targeting both lymphocyte function and macrophage function is more effective than either alone, and to examine the relative roles of each in decreasing tumor growth. Furthermore, since partial hepatectomy (PH) has been shown to be immunosuppressive and to accelerate the growth of hepatic tumor, we examined the effectiveness of these treatment strategies in the clinically relevant model of hepatic resection in the face of microscopic residual disease.
Materials and Methods
Animals. Male Buffalo rats (National Cancer Institute, Bethesda, MD) were housed in individual cages in a temperature-(22 Њ C) and humidity-controlled room with a 12-h day/night cycle. Animals were provided food (PMI Mills, St. Louis, MO) and water ad libitum. Food consumption and body weight were measured daily. All animals received care under approved protocols in compliance with Memorial Sloan-Kettering Cancer Center's Institutional Animal Care and Use Committee guidelines.
Tumors. A syngeneic tumor, Morris Hepatoma McA-RH7777 (ATCC No. CRL 1601; Rockville, MD), was maintained in culture and periodically implanted in flanks to ensure tumorigenicity.
Recombinant murine ␥ IFN. Recombinant murine ␥ IFN supplied by Genentech Inc. (South San Francisco, CA) was diluted with sterile water to 5 ϫ 10 4 U/100 ml before injection. This dosage has previously been shown to produce significant biological responses including enhanced expression of TNF ␣ receptors (16, 17) .
Operative procedures. All operative procedures were performed under pentobarbital anesthesia (25 mg/kg of body weight i.p.) via midline abdominal incision. 70% PH was performed according to the methods of Higgins and Anderson and include resection of the left and median lobes (2). Animals received 3 ml i.p. of normal saline prior to skin closure.
Splenocyte isolation. Animals underwent splenectomy under sterile conditions. Each spleen was placed in a petri dish with 10 ml of media (RPMI ϩ 10% FCS ϩ 50 g/ml gentamicin). Splenocytes were washed from the spleen by repeated resuspension with media, spun (1,500 rpm, 5 min) and subsequently resuspended in 5 ml of red cell lysis solution (8.8 g NaCl, 50 mM Tris, 10 ml NP-40, 1.68g NaF per liter). After 1 min, the solution was neutralized by the addition of 5 ml of media. Cells were spun (1,500 rpm, 10 min), washed 2 ϫ with media, and kept in culture in media supplemented with 30 U/ml IL-2 (Chiron Corp., Emeryville, CA) for 2 d prior to use.
Kupffer cell isolation. KC were obtained with standard collagenase perfusion and differential ultracentrifugation (18, 19) . Briefly, the portal vein was cannulated and the liver perfused in vivo with three different solutions: Leffert's solution with 0.5 mM/liter EGTA (38 Њ C, 10 min), Leffert's solution without EGTA (38 Њ C, 5 min), and Leffert's solution with 5 mM/liter CaCl 2 , 7 mg/ml bovine serum albumin and 0.2 mg/ml collagenase D (Boehringer Mannheim Co., Indianapolis, IN) (38 Њ C, 15 min). The liver was then removed, minced, passed through a 50-m nylon mesh into RPMI and centrifuged (50 g , 2 min). The supernatant was centrifuged (300 g , 10 min), and the pellet containing KC was resuspended in 20 ml of Media, layered onto an isoosmotic Percoll (Pharmacia Biotech Inc., Piscataway, NJ) gradient, and spun (800 g , 15 min). The band containing KC was harvested, diluted with equal volume PBS, and spun (800 g , 10 min). The pellet was resuspended in media ϩ 1% penicillin/streptomycin. Cells were counted, plated in 96-well plates (Costar Corp., Cambridge, MA), and incubated for 4 h. Non-adherent cells were washed off with media. This procedure yields cells which adhere, take up India ink uniformly, and stain positive with Wright-Giemsa stain (Baxter, McGaw Park, IL), confirming this procedure produced KC.
HSV vectors. The murine GM-CSF, human IL-2 and LacZ genes were cloned directionally into HSVprPUC which contains the HSV immediate early 4/5 promoter, a multiple cloning site, and an SV40 A sequence, and packaged as previously described (13) . RR1 cells (BHK cells stably transfected with the HSV IE3 gene) (20) , along with D30 EBA helper virus (21) (a strain 17-derived IE3 mutant deleted from codons 83 to 1236 and maintained in Dulbecco's modified Eagle medium (DME) containing high glucose [HG, 4.5 g/liter], 10% FCS, 1% penicillin/streptomycin, and 400 g/ml of bioactive geneticin [G418; Gibco BRL, Gaithersburg, MD] at 37 Њ C and 5% CO 2 ) were used for packaging HSV amplicons. To package amplicon vectors, 3 ϫ 10 6 RR1 cells were plated in media containing 10% FCS and transfected 4 h later by adding 40 l of Lipofectin (Gibco), waiting 5 min, and adding amplicon DNA solution dropwise (30 g at 1 g/ l in DME). 6 h later, plates were fed with media containing 5% FCS. 20 h after transfection, D30 EBA virus in 50-100 l was added to achieve an moi of 0.2. 5 ml of complete media with 5% FCS were added to each plate after 1 h, and amplicon virus stocks were harvested 2 d later. After overnight storage at 70 Њ C, fresh RR1 cells (4 ϫ 10 6 cells/60 mm plate) were infected with warmed (34 Њ C), sonicated virus stock. 2 d later, stocks were harvested and stored for subsequent use. HSVlac stocks were titered by an expression assay using NIH-3T3 cells plated (2 ϫ 10 5 cells/well of a 24-well plate) and infected with increasing volumes of virus stock in duplicate. 24 h after infection, cells were fixed and stained with 5-bromo-4-chloro-3-indolyl ␤ -D -galactoside (X-gal) using standard methods. The number of X-gal ϩ (blue) cells were counted, and titers were expressed as the number of blue forming units/ml. The D30 EBA helper virus in each stock was titered by plaque assay on RR1 cells, and the cytokine-containing vectors were titered by slot blot analysis (22). For slot blot analysis, viral DNA was extracted twice from packaged virus by phenol/chloroform, ethanol-precipitated with single-strand calf thymus DNA as carrier, denatured at room temperature with 0.2 N NaOH, 0.5 M NaCl for 10 min, and loaded on a nylon membrane with a slot blot apparatus. The membrane was backed for 2 h at 65 Њ C and probed with a [ 32 P]-labeled 435 bp SspI and PvuI fragment containing part of the ␤ -lactamase gene from pBR322 (nucleotides 3733-4168). After stringent washing (0.1 ϫ SSC 2 ϫ for 15 min), blots were exposed to x-ray film, and various timed exposures taken and densitometrically scanned (LKB Ultroscan; Pharmacia LKB Biotechnology Inc., Piscataway, NJ). Band densities and the titers of HSVil2 and HSV GM-CSF (expressed as particles/ml) calculated from the density relative to HSVlac given that this latter amplicon was titered by an expression assay, were compared. HSVlac titers were between 1-2 ϫ 10 6 blue forming units/ml as titered by expression and X-gal biochemistry on NIH 3T3 cells. The HSVil2 and HSVGM-CSF titers were between 1-2 ϫ 10 6 particles/ml. The ratio of D30 EBA helper virus to amplicon varied from 2:1 to 5:1. moi refers to the amplicon. Recombination for wild-type revertants was monitored by plaque assay on Vero cells and occurred at a frequency of 1 ϫ 10
In vitro production of cytokines. To assess in vitro production of cytokines, 10 6 hepatoma cells per 2 ml were plated in six-well plates (Costar), irradiated with 10,000 rad, and rested for 1 h. Cells were then exposed to HSVil2, HSVGM-CSF, HSVlac, or Media for 20 min at moi's of one and two and washed 2 ϫ with media. Cell culture supernatants were harvested on days 1, 2, 4, and 7 post-exposure, and cytokine levels were measured by ELISA (IL-2, R & D Systems, Minneapolis, MN; GM-CSF, Genzyme Corp., Cambridge, MA).
Effect of vaccination and ␥ IFN on hepatic tumor. Hepatoma cells in culture were irradiated with 10,000 rad, allowed to rest for 1 h, then exposed to HSVil2, HSVGM-CSF, HSVlac or media for 20 min at an moi of one. Cells were then washed 2 ϫ with media, and Statistical analysis. Statistical significance of differences in the number of liver nodules and percent specific lysis, expressed as mean Ϯ SEM, were analyzed using ANOVA or Student's t -test (SPSS Inc., Chicago, IL) as appropriate.
Results

In vitro and in vivo production of cytokines. Control cells not exposed to cytokine gene-containing vectors do not produce cytokines including IL-2, GM-CSF, ␥ IFN, IL-12, or TNF ␣ . No cytokines are seen immediately after transduction with HSVil2
and HSVGM-CSF and washing, indicating that proteins were not injected along with tumor cells. Cells exposed to HSVil2 or HSVGM-CSF produce nanogram quantities of these cytokines per 10 6 cells after vaccination (Figs. 1, A and B ) , peaking on day 1 and decreasing thereafter. The in vitro data correlate with the in vivo data: cytokines levels are seen only in the liver (IL-2, 461 pg/organ) and spleen (IL-2, 12 pg/organ) on day 2, but levels are below detectability on day 18. Cytokine levels were undetectable in heart, lung, serum, and kidney.
Effect of vaccination and ␥ IFN on hepatic tumor.
There was no significant effect of vaccination with irradiated cells or vaccination with irradiated cells transduced by HSVlac compared to injection of media alone. Animals immunized with IL-2-or GM-CSF-secreting cells or pretreated with ␥IFN had significantly fewer tumor nodules than all three control groups ( Fig.  2 , P Ͻ 0.001). Combination treatment with IL-2-or GM-CSFsecreting tumor cell vaccines and pretreatment with ␥IFN was more effective than any single treatment; complete responses were seen in 8 of 11 IL-2 animals and 4 of 12 GM-CSF animals (Fig. 2) . No animal treated with ␥IFN alone was without tumor.
Effect of immunization and ␥IFN on hepatectomy-enhanced tumor growth. Hepatectomy significantly increased the number of tumor nodules compared to controls (Fig. 3 , NoHep vs. CTRL/Sal, P Ͻ 0.001). Animals immunized with IL-2-or GM-CSF-secreting cells or pretreated with ␥IFN had significantly fewer tumor nodules than control (Fig. 3 , CTRL/Sal vs. all others P Ͻ 0.001). Combination treatment with cytokine-secreting vaccines and pretreatment with ␥IFN was more effective than any single treatment. (Fig. 3, P Ͻ 0.01) . Thus, combination therapy of cytokine vaccines and ␥IFN is effective in decreasing tumor growth in the setting of hepatectomy.
Effect of vaccination and ␥IFN on splenocyte and KC function. Vaccination with HSVlac or irradiated cells had no significant effect on either KC or splenocyte activity. Splenocytes from animals vaccinated by either HSVil2 or HSVGM-CSF had significantly greater killing of targets than splenocytes from control or ␥IFN-treated animals (Figs. 4, A and B) . ␥IFN did not appear to affect splenocyte lytic activity. There were no significant differences among any of the three control groups; to simplify the illustration, the three control groups have been pooled. KC from rats pretreated with ␥IFN had significantly greater killing of targets than KC from controls (Figs. 5, A and  B) . KC from rats vaccinated with HSVil2 also had significantly greater killing of targets than KC from controls (P Ͻ 0.05), but not as great as ␥IFN. Vaccines secreting GM-CSF did not seem to affect KC activity.
Discussion
Recent studies have focused on the use of cytokines to enhance the immune system in an attempt to decrease tumor growth (8, 9, 24) . Systemic administration of cytokines is accompanied by unwanted serious side effects (5, 7). Transfer of cytokine genes into tumor cells gives the advantage of being able to produce high concentrations of cytokines of interest in the area of putative tumor antigens. Also, as identification of specific cytokine genes increases, we are able to transfer specific isolated genes to determine their role in immunomodulation.
The fundamental principles of immunotherapy for solid tumors are the suppositions that tumor antigens can be recognized, and that animals can elicit a tumor-specific immune response (5, 25) . In this experiment, we vaccinated animals with irradiated tumor cells that had been infected by HSV vectors, and were producing IL-2 or GM-CSF (cytokines which have been shown previously to stimulate antitumor immune responses) (8) (9) (10) (11) 26) .
HSV vectors are efficient and effective in producing high levels of cytokines locally and generating an immune response (13, 14, 27) . In this experiment, cytokine production was seen only in the target organs, the liver and the spleen. Furthermore, production was transient, with levels returning to below detectability prior to the subsequent tumor challenge 3 wk later. Thus, any effects on cellular immunity and tumor growth were not dependent upon ongoing cytokine production during challenge.
Vaccination with HSVil2 or HSVGM-CSF reduced the amount of tumor in the liver after subsequent challenge with highly tumorigenic doses of unmodified tumor cells. The results are not simply due to the prior presence of tumor antigen, since irradiated cells alone did not reduce tumor. Nor was the effect of vaccination due to the presence of HSV, since treatment with HSVlac did not cause a decrease in tumor. Even in the setting of PH, which has been shown to be immunosuppressive and to accelerate the growth of hepatic tumor, vaccination was effective. Combination therapy abrogated the effect of PH, for animals so treated had no more tumor than the non-hepatectomized control.
Production of cytokines in the presence of tumor antigens induces a lymphocyte immune response, as evidenced by the increased tumoricidal activity of splenocytes from vaccinated animals. Generating an immune response requires a simple vaccination protocol utilizing fresh tumor cells, a 20-min transduction, and a single injection into the spleen and portal system to result in finite cytokine production. Such a protocol is clinically feasible.
Perioperative immunostimulation has been examined as a means of decreasing tumor (28, 29) . In the current study, we employed ␥IFN, a multifunctional protein with a wide range of immunostimulatory effects, for immunoactivation (26, 30) . In this experiment, pretreatment with ␥IFN resulted in decreased hepatic tumor after splenic injection of tumor. This effect is due to stimulation of KC causing increased tumoricidal activity of these tissue-based macrophages (4, 26) .
The combination of IL-2 and ␥IFN has begun to be examined in clinical trials (31) . In the current study, the combination of ␥IFN and cytokine vaccines was more effective than either method alone, and, in many cases, prevented the establishment and growth of tumor in the liver after subsequent challenge with highly tumorigenic doses of unmodified tumor cells. Whether these effects were synergistic or simply additive is difficult to distinguish. ␥IFN did not appear to increase the tumoricidal activity of splenocytes; the cytokine vaccines appeared to have little direct effect on macrophages. However, in addition to augmenting macrophage kill, ␥IFN may also improve antigen processing, thereby increasing the efficiency of T-cell mediated immunity.
Liver cancer effects over 2 million people worldwide per year. Surgical resection is the most effective treatment, yet the most common site for recurrence after resection is within the liver itself, indicating that microscopic residual disease is left behind after "curative" surgery. Experimental evidence indicates that hepatic resection is immunosuppressive and enhances the growth of residual tumor (19, 32) . The current experiment confirms that tumor growth in the liver is enhanced by PH. Moreover, the current study demonstrates that even in the immunosuppressive setting of liver resection, macrophage, and lymphocyte anti-tumor function can be restored by ␥IFN administration and tumor immunization.
Clinical studies have already shown the feasibility of extracting tumor, transducing cells with genes, and returning the transduced cells to the host (33); HSV vectors are potentially useful tools for this clinical application because they can transfect irradiated, non-replicating cells rapidly and efficiently. In experiments using human tumors isolated from patients in the operating room, the entire isolation, transduction with HSV vectors, and irradiation process was uniformly less than 240 min, and was free of the technical problems of primary tissue culture (34) . ␥IFN has been used in clinical trials for several years with varying effectiveness as a therapeutic tool for large tumor burdens. In our clinically relevant model of hepatectomy and local recurrence, these two treatments retarded growth of microscopic residual metastases. These data encourage future studies of the use of an immunomodulator, such as ␥IFN, coupled with directed vaccine gene therapy in the adjuvant treatment of the large numbers of patients undergoing liver resection for cancers.
